Navigating Oncology Rivals: AbbVie’s Strategic Position Under Scrutiny

Monday’s trading spotlight falls on AbbVie as the market weighs competing clinical data releases. The pharmaceutical giant finds itself at a crossroads, contending with a fresh challenge to a key cancer therapy while simultaneously showcasing robust results from its own development pipeline. Substantial institutional buying activity further underscores a vote of long-term confidence in the company’s direction.

Institutional Confidence and Analyst Perspectives

Amidst short-term competitive noise, major investors are demonstrating conviction. 1832 Asset Management L.P. boosted its stake in AbbVie by 158.7% during the second quarter of 2025. Federated Hermes Inc. also made a significant addition to its holdings. This sentiment is echoed by equity researchers. Piper Sandler reaffirmed its “Overweight” rating on Friday, setting a price target of $289 per share. This projection suggests an approximate 27% upside from current trading levels.

This faith is rooted in AbbVie’s ongoing strategic transition. The company’s third-quarter performance exceeded expectations, leading to an upward revision of its full-year guidance. Growth drivers Skyrizi and Rinvoq posted strong gains, effectively offsetting declining revenue from the patent-expired Humira. Furthermore, the recent dividend increase—marking the 53rd consecutive annual raise—reinforces its reputation as a reliable income stock.

Should investors sell immediately? Or is it worth buying AbbVie?

Competitive Data and Pipeline Countermeasures

The release of pivotal studies at the recent American Society of Hematology (ASH) annual meeting framed the current dynamic. Data indicated that Eli Lilly’s Jaypirca achieved higher response rates than AbbVie’s Imbruvica in treating certain leukemia forms. This presents an additional challenge for Imbruvica, a key revenue generator already facing pricing pressures and competitive threats.

However, AbbVie presented compelling counterpoints from its research portfolio. A phase 3 trial for the combination therapy involving epcoritamab reported an impressive overall response rate of approximately 95% for a lymphoma indication. Additional data supports the company’s strategy of transitioning patients to the newer therapy, Venetoclax. These pipeline successes are central to AbbVie’s broader shift away from reliance on its older blockbuster drugs.

Quarterly Outlook and Strategic Levers

Market attention now turns to how analysts will incorporate the ASH data into their revenue models for AbbVie’s oncology division. For the fourth quarter, management has provided an adjusted earnings per share forecast in the range of $3.32 to $3.36. The ambitious targets for Skyrizi and Rinvoq, which are projected to deliver combined revenues exceeding $31 billion by 2027, remain the central lever for the company’s future financial performance.